LEXINGTON, Mass. - Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology firm focused on neurogenetic medicines with a market capitalization of $290 million, announced today it is reassessing its ...

Bitcoin is holding above $95,000 despite heavy selling pressure, briefly dipping to $94,726 on Feb. 9 before recovering.

Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR – Get Free Report) have been given an average recommendation of “Buy” by the nine brokerages that are covering the stock, MarketBeat.com reports.

The PSAP Voyager hydrophones are self-contained, as they use the temperature difference in the surrounding water to power ...

Voyager Therapeutics (NASDAQ:VYGR – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in ...

(Voyager), this formalizes the company's position as a trusted leader in national security and space innovation. This strategic shift highlights Voyager's capabilities and position across broad ...

The confidence in Voyager Therapeutics (NASDAQ:VYGR)' stock is further supported by the company's strategic collaborations, such as those with Neurocrine (NASDAQ:NBIX) Biosciences, which continue to ...

“This is more than a name change — it’s a declaration to the broader market of our expanded capabilities,” Dylan Taylor, chairman and CEO of Voyager, said in a statement. “It positions ...

There is no word yet on when the IPO will happen. According to Voyager, it is still working out "the number of shares to be ...